Brief: Ovid Therapeutics- On May 10, Takeda Notified Co Takeda Planned To Announce Two Pivotal Phase 3 Programs Evaluating Soticlestat Are Likely To Be Delayed

Ovid Therapeutics

11/05/2022 13:37

May 11 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS- ON MAY 10, TAKEDA NOTIFIED CO TAKEDA
PLANNED
TO ANNOUNCE TWO PIVOTAL PHASE 3 PROGRAMS EVALUATING SOTICLESTAT
ARE LIKELY TO BE DELAYED
    * OVID THERAPEUTICS INC - TAKEDA DISCLOSED IT IS WORKING ON
MULTIPLE APPROACHES TO MINIMIZE DELAYS
    * OVID THERAPEUTICS INC - TAKEDA STATED THAT STUDIES ARE
ACTIVELY
RECRUITING PATIENTS AND REMAIN ONE OF TAKEDA'S HIGHEST PRIORITY,
LATE-STAGE, PROGRAMS

Further company coverage:  OVID.O 

 ((Reuters.Briefs@thomsonreuters.com;))